Stockscreener 앱 받기
2.64
2.94%
-0.08
시간 외 거래:
2.70
0.06
+2.27%
전일 마감가:
$2.72
열려 있는:
$2.83
하루 거래량:
269.55K
Relative Volume:
2.78
시가총액:
$44.59M
수익:
$19.91M
순이익/손실:
$-127.11M
주가수익비율:
-3.3872
EPS:
-0.7794
순현금흐름:
$-132.44M
1주 성능:
-27.67%
1개월 성능:
-22.35%
6개월 성능:
-48.74%
1년 성능:
-45.79%
1일 변동 폭
$2.64
$2.96
1주일 범위
$2.64
$3.76
52주 변동 폭
$2.64
$8.95
Affimed N V Stock (AFMD) Company Profile
AFMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| AFMD | 2.64 | 44.59M | 19.91M | -127.11M | -132.44M | -0.7794 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-12 | 개시 | H.C. Wainwright | Buy |
| 2022-10-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-10-21 | 개시 | Truist | Buy |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2018-08-28 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2016-08-12 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-05-19 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2015-12-10 | 개시 | Laidlaw | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-09-09 | 개시 | Jefferies | Hold |
| 2015-08-06 | 재확인 | Oppenheimer | Outperform |
| 2015-06-22 | 재확인 | Jefferies | Buy |
모두보기
Affimed N V 주식(AFMD)의 최신 뉴스
Affimed Q3 2024 Earnings Preview - MSN
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey
10 Best German Stocks To Buy Now - Insider Monkey
Cantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD) - MarketBeat
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat
Earnings call: Affimed reports promising results and strategic focus - Investing.com India
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance
Affimed Reports Q3 2024 Financial Results and Updates - TipRanks
Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle
Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada
Affimed Faces Growing Losses Amid Financial Struggles - TipRanks
Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times
Affimed N.V.: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
Affimed Q3 Revenue Drops 90%, but Net Loss Narrows as R&D Costs Decline | AFMD Stock News - StockTitan
Affimed (AFMD) Scheduled to Post Quarterly Earnings on Thursday - Defense World
Affimed to Report Third Quarter 2024 Financial Results and Corporate Update on November 14, 2024 - Marketscreener.com
Affimed (AFMD) Scheduled to Post Earnings on Thursday - MarketBeat
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 - GlobeNewswire
Affimed (AFMD) Sets Q3 2024 Earnings Call for Nov 14: Immuno-Oncology Updates Ahead | AFMD Stock News - StockTitan
Affimed (NASDAQ:AFMD) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Affimed Announces Acceptance of Three Abstracts at the 2024 - GlobeNewswire
Affimed to Present Promising AML Treatment Data at ASH 2024 Annual Meeting | AFMD Stock News - StockTitan
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma - Yahoo Finance UK
Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Affimed (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - MarketBeat
683 Capital Management, LLC Expands Stake in Affimed NV - Yahoo Finance
Affimed Appoints New Director Amid Strategic Moves - TipRanks
Affimed N : Annual General Meeting Results Form 6 K - Marketscreener.com
Affimed N : Presentation - Marketscreener.com
Analysts Set Affimed (NASDAQ:AFMD) Target Price at $20.00 - MarketBeat
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Affimed appoints Shawn Leland as chief executive officer - MSN
Affimed (NASDAQ:AFMD) Sees Significant Decrease in Short Interest - MarketBeat
AFMDAffimed N.V. Latest Stock News & Market Updates - StockTitan
Affimed N.V. Announces Upcoming EGM - TipRanks
Affimed to Present at the Cantor Global Healthcare Conference 2024 - GlobeNewswire
Affimed (NASDAQ:AFMD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Affimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms Buy Rating for Affimed (NASDAQ:AFMD) - MarketBeat
Earnings call: Affimed reports promising clinical results and stable finances By Investing.com - Investing.com Australia
Earnings call: Affimed reports promising clinical results and stable finances - Investing.com
Affimed NV (AFMD) Q2 2024 Earnings Call Transcript Highlights: F - GuruFocus.com
Affimed N.V.: Q2 Earnings Snapshot - New Haven Register
Affimed N V (AFMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):